Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

Zomedica Corp.’s (ZOM) stock soars due to positive announcement

Related Topics

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

Zomedica Corp.’s (NYSE: ZOM) stock has soared by 8.73% to the current value of $2.49.  In the after-hours market, the ZOM stock rose by %10.84.

One of the major news that comes adjacent to the positive movement in the ZOM stock is its ability to sell its first commercial unit of the unique and valuable diagnostic tool kit. This tool kit was delivered to the veterinary market slightly ahead of the announced schedule.

About Zomedica Corp

ZomedicaCorp (NYSE American: ZOM) is a veterinary health company that creates commercial products for pets, specifically cats and dogs. They focus primarily on delivering and innovating products that tend to be the clinical veterinarians’ unmet needs. Market and business-wise, this is a brilliant tactic in which the Corp. stays ahead of the competition with its differentiated products that have more probability of being recommended by the clinical veterinarians.

TRUFORMA delivered before its announced sale date

The kit that has been tailor-made and sold is known as TRUFORMA, which was delivered ahead of the announced 30th March date. What this instrument does is that it is an on-site canine eACTHessay that is created to eliminate the risk of sample transport error. Furthermore, it aids in the diagnosis of adrenal disease.

TRUFORMA was made true thanks to the collaboration of the employees at ZOM and a team of scientists/researchers at the Qorvo Biotechnologies LLC that worked as a development partner. Qorvo Biotechnologies, with the help of their special Bulk Acoustic Wave (BAW) radio frequency (RF) technology, can disrupt the veterinarian market with this innovative milestone in the form of veterinarian diagnostic.

TRUFORMA sold to an established veterinary hospital

The first official purchaser of the veterinarian diagnostic system-TRUFORMA is Jason Berg, DVM (Doctor of Veterinary Medicine), DACVIM (Diplomate, American College of Veterinary Internal Medicine). This is again a very clever marketing tactic because Jason Berg is the president and founder of Guardian Veterinary Specialists, an emergency critical care hospital located in New York. Dr. Berg is recognized professionally for his work as a veterinary internist and neurologist. Furthermore, Dr. Berg is a lecturer and a researcher who published several articles and professional journals that American Veterinary Medical Association has reviewed.

What makes TRUFORMA so unique?

Apart from this eACTH cortisol assay, there are two more out of the five initial assays available for commercial selling ahead of their time. T4 and endogenous ACTH are expected to be available soon while TSH, cortisol, and total T4 being commercially ready.

This news is good for the ZOM stock’s positive movement because, in the field of clinical veterinary, vets have to depend on serum cortisol measurements to cater to adrenal diseases in dogs. With TRUFORMA’s enhanced efficacy and accuracy in cortisol assay, what is essentially going to revolutionize is how veterinarians will treat life-threatening adrenal diseases and give comforting news to the owners of the pets.

Latest Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam